Fundamental Analysis Report – Nifty500 Healthcare – 12 August 2025

1. Index Overview

The Nifty500 Healthcare Index includes large, mid, and small-cap companies in pharmaceuticals, biotechnology, diagnostics, hospitals, and healthcare services. This broader index reflects the performance of India’s most significant healthcare players, benefiting from strong domestic demand, global generic exports, and increasing healthcare infrastructure investments. Risks include regulatory hurdles, raw material dependency, and currency fluctuations.

2. Institutional Holdings & Fund Activity

FII/DII Movement (Index-Wide – Latest Quarter):

• Foreign Institutional Investors (FII): ↑ 3.2% in healthcare heavyweights

• Domestic Institutional Investors (DII): ↑ 2.4% driven by healthcare-focused funds

Impact: Institutional accumulation indicates confidence in India’s healthcare growth story and export potential.

3. Financial Health Snapshot (Index Averages)

Debt-to-Equity: 0.38

Return on Equity (ROE): 15.8%

Return on Capital Employed (ROCE): 14.9%

Comment: The sector maintains a healthy balance sheet, supported by strong margins and steady cash flows.

4. Valuation Check

Current P/E (Index Avg): 23.0

5-Year Avg P/E: 21.5

Index Positioning: Slightly Overvalued

Reason: Positive earnings momentum and defensive nature have driven valuations slightly above historical averages.

5. Dividend Insight (Top 5 Constituents Average)

Dividend Yield: 1.2%

Payout Ratio: 24%

Dividend Stability Score: Strong

Note: Established healthcare players maintain consistent dividend payouts while balancing R&D and expansion.

6. IPO Corner (Recent Healthcare IPOs)

Latest IPO: BioCare Pharma Ltd (07 Aug 2025)

IPO Price Band: ₹410–₹420

Subscription Status: 6.1x oversubscribed

Post-Listing Performance: +12% from issue price

Long-Term Outlook: Positive, supported by pipeline expansion and export opportunities.

7. Sector Business Model Deep Dive

Core Business: Pharmaceutical manufacturing, biotechnology, diagnostics, hospital services, and wellness products.

Key Revenue Sources: Drug manufacturing, exports, hospital treatments, diagnostic testing, and preventive care.

Growth Drivers: Global demand for generics, domestic healthcare spending, expansion of hospital chains, and medical tourism.

Risks: Regulatory approvals, raw material price volatility, patent expirations, and compliance requirements.

8. Key Takeaways

• Large-cap healthcare leaders provide stability while mid-small caps offer growth opportunities.

• Strong export markets and domestic healthcare demand support revenue growth.

• Valuations are slightly stretched, requiring selective buying.

9. Top & Bottom Performers in Nifty500 Healthcare Index

Company	Revenue (₹ Cr)	Net Profit (₹ Cr)	Gross EBITDA (₹ Cr)	Net EBITDA (₹ Cr)	Operating Expenses (₹ Cr)	Performance Rank
Sun Pharma	45,000	8,200	14,500	14,000	30,500	Top Performer 1
Dr. Reddy’s Labs	23,500	4,200	7,800	7,500	15,700	Top Performer 2
Apollo Hospitals	16,000	2,000	3,800	3,650	12,200	Top Performer 3
Divi’s Labs	9,800	2,100	3,000	2,900	6,800	Top Performer 4
Fortis Healthcare	6,300	850	1,400	1,350	4,950	Top Performer 5
Nectar Lifesciences	1,000	-50	100	90	1,100	Bottom Performer 1
Sequent Scientific	1,100	-60	120	110	1,160	Bottom Performer 2
Shalby Ltd	750	-20	80	75	770	Bottom Performer 3
Strides Pharma	3,800	120	500	480	3,300	Bottom Performer 4
Indoco Remedies	1,200	30	150	140	1,050	Bottom Performer 5

10. Market Timing Insight

The current Put-Call Ratio (PCR) is high, suggesting overbought conditions in the short term. While the Nifty500 Healthcare Index is fundamentally strong, near-term pullbacks are possible. Staggered buying is recommended for long-term investors, while short-term traders should await better entry points.

11. Short, Mid, and Long-Term Investment Strategies

Short-Term Strategy: Trade momentum in stocks like Apollo Hospitals and Dr. Reddy’s Labs around earnings announcements and sector news, with tight stop-losses.

Mid-Term Strategy: Accumulate leaders like Sun Pharma and Divi’s Labs on dips, targeting 15–20% returns over 6–12 months.

Long-Term Strategy: Hold a diversified basket of large and mid-cap healthcare stocks for 3–5 years to benefit from structural healthcare growth trends.

12. Key Technical Levels – Nifty500 Healthcare Index

Time Frame	Critical Support Levels	Critical Resistance Levels
Short-Term (1–3 months)	14,200 / 13,800	15,500 / 15,900
Mid-Term (6–12 months)	13,000 / 12,500	16,500 / 17,000
Long-Term (3–5 years)	11,800 / 11,000	18,500 / 19,200

13. Upcoming Important Events in the Healthcare Sector (Next 3 Months)

Date	Event
15 Aug 2025	Government policy announcement on pharma incentives.
28 Aug 2025	Quarterly results season for healthcare heavyweights.
12 Sep 2025	India Medical Expo – Focus on biotech partnerships.
05 Oct 2025	Global Generics Conference – Export growth opportunities.
15 Oct 2025	Union Health Ministry review on public healthcare spending.
10 Nov 2025	Q2 FY25 earnings results for major healthcare companies.

📌 Disclaimer – aiTrendview.com

This report has been prepared by aiTrendview.com for informational and educational purposes only. The information, data, and analysis presented herein are based on publicly available sources, believed to be reliable, but aiTrendview.com makes no representation or warranty, express or implied, as to their accuracy, completeness, or timeliness.

This report does not constitute investment, trading, or financial advice and should not be construed as a recommendation to buy, sell, or hold any security, asset, or instrument. All investments involve risks, including possible loss of principal. Past performance is not indicative of future results.

Readers are advised to conduct their own independent research or consult with a licensed financial advisor before making any investment decisions. aiTrendview.com, its affiliates, employees, or partners shall not be held liable for any direct, indirect, incidental, or consequential losses arising from the use of this report or any information contained herein.

By accessing and using this report, you agree to this disclaimer in full.